DE9320925U1 - Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen - Google Patents

Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen

Info

Publication number
DE9320925U1
DE9320925U1 DE9320925U DE9320925U DE9320925U1 DE 9320925 U1 DE9320925 U1 DE 9320925U1 DE 9320925 U DE9320925 U DE 9320925U DE 9320925 U DE9320925 U DE 9320925U DE 9320925 U1 DE9320925 U1 DE 9320925U1
Authority
DE
Germany
Prior art keywords
treatment
optically pure
allergic disorders
pure isomers
terfenadine metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE9320925U
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Georgetown University
Original Assignee
Georgetown University
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE9320925(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Georgetown University, Sepracor Inc filed Critical Georgetown University
Publication of DE9320925U1 publication Critical patent/DE9320925U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
DE9320925U 1992-08-03 1993-08-03 Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen Expired - Lifetime DE9320925U1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92415692A 1992-08-03 1992-08-03
US92418292A 1992-08-03 1992-08-03
EP93918584A EP0701443B2 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten

Publications (1)

Publication Number Publication Date
DE9320925U1 true DE9320925U1 (de) 1995-08-31

Family

ID=27129882

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69334008T Expired - Lifetime DE69334008T2 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen
DE0701443T Pending DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DE69334145T Expired - Lifetime DE69334145T2 (de) 1992-08-03 1993-08-03 Terfenadincarboxylat und die Behandlung von Hautreizung
DE69316660T Expired - Lifetime DE69316660T3 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
DE9320925U Expired - Lifetime DE9320925U1 (de) 1992-08-03 1993-08-03 Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE69334008T Expired - Lifetime DE69334008T2 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen
DE0701443T Pending DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DE69334145T Expired - Lifetime DE69334145T2 (de) 1992-08-03 1993-08-03 Terfenadincarboxylat und die Behandlung von Hautreizung
DE69316660T Expired - Lifetime DE69316660T3 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten

Country Status (24)

Country Link
US (1) US5375693A (de)
EP (4) EP0701443B2 (de)
JP (6) JP3041954B2 (de)
KR (1) KR950702420A (de)
AT (3) ATE162399T1 (de)
AU (3) AU675240B2 (de)
BR (1) BR9306841A (de)
CA (1) CA2141572C (de)
CZ (1) CZ27495A3 (de)
DE (5) DE69334008T2 (de)
DK (3) DK0701443T4 (de)
ES (3) ES2086270T5 (de)
FI (1) FI950467A (de)
GB (1) GB2284351B (de)
GR (3) GR960300024T1 (de)
HK (1) HK1045806B (de)
HU (1) HU226242B1 (de)
NO (1) NO310644B1 (de)
PL (1) PL174373B1 (de)
PT (2) PT815860E (de)
RO (1) RO116043B1 (de)
RU (1) RU2167657C2 (de)
SK (1) SK12495A3 (de)
WO (1) WO1994003170A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ251834A (en) * 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
PT815860E (pt) * 1992-08-03 2006-08-31 Sepracor Inc Carboxilato de terfenadina e tratamento de desordens alergicas.
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
KR100387347B1 (ko) 1993-06-24 2003-11-28 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체 및 그의 제조 방법
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
DE69527429T2 (de) 1994-05-18 2003-03-20 Aventis Pharma Inc Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
KR100405116B1 (ko) * 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
TR200000517T2 (tr) * 1997-08-26 2000-08-21 Hoechst Marion Roussel, Inc. Piperidinoalkanol-Konjesyon azaltıcıdan oluşan kombinasyona yönelik farmasötik kompozisyon.
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
MXPA03009259A (es) * 2001-04-09 2004-06-03 Teva Pharma Polimorfos de clorhidrato de fexofenadina.
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
DE03757471T1 (de) * 2002-06-10 2005-09-01 Teva Pharmaceutical Industries Ltd. Polymorphe form xvi von fexofenadin-hydrochlorid
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20050256163A1 (en) * 2004-04-26 2005-11-17 Ilan Kor Crystalline forms of fexofenadine hydrochloride and processes for their preparation
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
EP1685106A2 (de) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadin-kristallform und verfahren zu deren herstellung
BRPI0517166A (pt) * 2004-12-09 2008-09-30 Celgene Corp uso de d-treo-metilfenidato ou um sal do mesmo
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
EP2420236B1 (de) * 2007-04-13 2015-01-14 Southern Research Institute Terfenadine als Anti-Angiogenese-Mittel
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
WO2014052836A2 (en) 2012-09-27 2014-04-03 Dunman Paul M Methods and compositions for treating infection
EP3273952B1 (de) 2015-03-26 2022-06-15 Sen-Jam Pharmaceutical LLC Kombination von naproxen und fexofenadine zur hemmung von symptomen im zusammenhang mit veisalgia
DE102017130361A1 (de) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
DK0635004T3 (da) * 1992-04-10 2002-11-11 Merrell Pharma Inc 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
NZ251834A (en) 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
PT815860E (pt) * 1992-08-03 2006-08-31 Sepracor Inc Carboxilato de terfenadina e tratamento de desordens alergicas.
KR100387347B1 (ko) * 1993-06-24 2003-11-28 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체 및 그의 제조 방법
CN1168717C (zh) * 1993-06-25 2004-09-29 默里尔药物公司 用于制备抗组胺哌啶衍生物的新中间体
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date
PL307339A1 (en) 1995-05-15
DK0701443T4 (da) 2000-12-18
ES2284740T3 (es) 2007-11-16
AU675240B2 (en) 1997-01-30
NO950374L (no) 1995-03-29
FI950467A0 (fi) 1995-02-02
DE69316660D1 (de) 1998-02-26
GB2284351A (en) 1995-06-07
ATE322899T1 (de) 2006-04-15
US5375693A (en) 1994-12-27
DE69316660T2 (de) 1998-05-07
PT1214937E (pt) 2007-07-25
NO310644B1 (no) 2001-08-06
HU9500313D0 (en) 1995-03-28
GR960300024T1 (en) 1996-05-31
HK1045806A1 (en) 2002-12-13
ATE162399T1 (de) 1998-02-15
DE69334008D1 (de) 2006-05-24
AU7182296A (en) 1997-01-30
JP2000086512A (ja) 2000-03-28
GR3026530T3 (en) 1998-07-31
JP3041954B2 (ja) 2000-05-15
ES2257757T3 (es) 2006-08-01
GB2284351B (en) 1996-11-27
DK0701443T3 (da) 1998-02-09
JP2000086513A (ja) 2000-03-28
EP0815860A2 (de) 1998-01-07
EP0701443A1 (de) 1996-03-20
ATE363283T1 (de) 2007-06-15
DE69334008T2 (de) 2006-10-19
ES2086270T5 (es) 2001-02-01
HU226242B1 (en) 2008-07-28
JPH08500348A (ja) 1996-01-16
JP2000086516A (ja) 2000-03-28
DK0815860T3 (da) 2006-08-14
DE69334145T2 (de) 2008-01-24
JP3288660B2 (ja) 2002-06-04
KR950702420A (ko) 1995-07-29
DE701443T1 (de) 1997-01-30
RO116043B1 (ro) 2000-10-30
FI950467A (fi) 1995-03-31
EP0815860A3 (de) 1998-01-14
PT815860E (pt) 2006-08-31
AU4798693A (en) 1994-03-03
RU95107881A (ru) 1996-11-27
DK1214937T3 (da) 2007-09-17
JP2000086514A (ja) 2000-03-28
EP1688142A1 (de) 2006-08-09
DE69316660T3 (de) 2001-04-05
EP1214937A2 (de) 2002-06-19
GB9502183D0 (en) 1995-03-22
NO950374D0 (no) 1995-02-01
CZ27495A3 (en) 1996-09-11
JP3288661B2 (ja) 2002-06-04
ES2086270T1 (es) 1996-07-01
DE69334145D1 (de) 2007-07-12
EP0815860B1 (de) 2006-04-12
JP2000086515A (ja) 2000-03-28
EP0701443B1 (de) 1998-01-21
WO1994003170A1 (en) 1994-02-17
CA2141572C (en) 2001-02-06
JP3037697B2 (ja) 2000-04-24
SK12495A3 (en) 1997-01-08
JP3288662B2 (ja) 2002-06-04
RU2167657C2 (ru) 2001-05-27
HK1045806B (zh) 2008-03-14
AU1842999A (en) 1999-04-29
CA2141572A1 (en) 1994-02-17
GR3035417T3 (en) 2001-05-31
EP0701443B2 (de) 2000-11-22
BR9306841A (pt) 1998-12-08
EP1214937A3 (de) 2002-10-30
PL174373B1 (pl) 1998-07-31
ES2086270T3 (es) 1998-03-01
EP1214937B1 (de) 2007-05-30
HUT71889A (en) 1996-02-28

Similar Documents

Publication Publication Date Title
DE9320925U1 (de) Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
WO1989006962A1 (en) Silver sulfadiazine-containing agent for topical external therapy